Molotinib: What kind of drug is this? What are the mechanisms of action and indications?

Molotinib (Ojjaara) is a new type of targeted therapy drug that is an inhibitor of Janus Kinase (JAK) 1 and 2. This drug has received widespread attention from the medical community in recent years, especially as it provides a new treatment option for patients with certain specific blood diseases and immune diseases.

The mechanism of action of molotinib is mainly by inhibiting the activities ofJAK1 and JAK2, thereby blocking the signal transduction of multiple inflammatory cytokines. These cytokines play key roles in a variety of diseases, including but not limited to myelofibrosis, rheumatic diseases, and certain neoplastic diseases. By inhibiting the action of these cytokines, molotinib can reduce inflammation and alleviate the condition.

In terms of indications, molotinib is currently approved for the treatment of moderate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis in adults with anemia (post-polycythemia vera and post-essential thrombocythemia). The drug is a once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. To date, it is the only approved drug for patients with newly diagnosed and previously treated myelofibrotic anemia that addresses the main manifestations of the disease, namely anemia, systemic symptoms, and splenomegaly (enlarged spleen), thereby improving patients' quality of life.

In addition, molotinib is also being studied for the treatment of other diseases related to abnormalities in theJAK signaling pathway, such as rheumatoid arthritis, psoriasis and other autoimmune diseases. A common feature of these diseases is overactivation of the immune system, leading to inflammation and tissue damage. By modulating the immune response, molotinib is expected to provide new treatment strategies for these patients.

In general, molotinib, as a new type of JAK inhibitor, provides new treatment hope for refractory diseases such as myelofibrosis through its unique mechanism of action. At present, the drug is only sold overseas, and a box costs about more than 50,000 yuan. Patients should be sure to purchase through formal channels and pay attention to distinguish authenticity from fake.